Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Tacalcitol is a vitamin D analog with little effect on calcium metabolism. It has actions and uses similar to those of calcipotriol; indicated in the treatment of mild to moderate plaque psoriasis. Topical application as a lotion or ointment at 0.0004%.
At the time of the last update, we found no published data on its excretion in breast milk.
There is negligible systemic absorption (< 0.5%) of the drug after application of tacalcitol to the skin (AEMPS 2018, Peters 1997), which together with its high binding to plasma proteins makes it unlikely that significant levels can be reached in breast milk; it is not necessary to interrupt lactation during treatment. (Almirall 2020)
No alterations in calcemia or calciuria secondary to treatment have been observed. (Peters 1997)
Do not apply on the breast to avoid ingestion by the infant; if necessary, apply after a feeding and rinse well with water before the next feeding.